An experimental study of buckwheat polysaccharide in adjuvant therapy for S180 sarcoma mice
More details
Hide details
Department of Rehabilitation Medicine, Baoding Second Hospital, Baoding, China
Department of Neurosurgery, Baoding Second Hospital, Baoding, China
Department of Pharmacology, North China University of Science and Technology, Tangshan, Hebei, China
Submission date: 2019-05-23
Final revision date: 2019-12-24
Acceptance date: 2019-12-24
Online publication date: 2020-07-02
Arch Med Sci 2023;19(1)
To discuss the auxiliary therapeutic effect of buckwheat polysaccharide (BP) on S180 sarcoma.

Material and methods:
Buckwheat polysaccharide was extracted with water and precipitated with ethanol. Solid tumor and ascites tumor mice models were established. The mice in the high, medium and low dosing groups (n = 24, each group) had their stomachs filled with different doses of BP. The cyclophosphamide (CTX) group and the model group (n = 24, each group) were used as control groups. The influence on the life cycle, the rate of suppressing the tumor, the thymus index, and the spleen index were evaluated. Tumor cells were cultured in vitro and intervened with drugs; flow cytometry was used to detect the changes in the cell cycle.

Buckwheat polysaccharide significantly improved the lifespan and survival rate of the mice. The group of mice treated with the medium dose showed the best survival rate when compared to the ones that received high and low doses of BP (p < 0.01). The tumor cells cultured in vitro were arrested in the G0/G1 phase to some extent (p > 0.05). The cyclophosphamide arrested the cycle of the tumor cells in the G2/M period (p < 0.01). Buckwheat polysaccharide could increase the thymus index, spleen index and the rate of suppressing the tumor, but the differences were not statistically significant.

Buckwheat polysaccharide had no obvious effect in inhibiting the growth of tumors, but it significantly extended the lifespan, increased the survival rate and reduced the toxic effect of CTX.